不过我不玩了,凡是我赚了钱了再玩基本就是亏,还是眼不见为净查看全文
chuminhua2019-12-14 11:38
12/13,BioLineRx公司$BioLineRx(BLRX)$ 在欧洲肿瘤内科学会免疫肿瘤学大会(ESMO IO)上公布了该公司开发的BL-8040与PD-1抗体Keytruda,以及化疗联用,治疗转移性胰腺癌患者的2a期临床试验结果。BL-8040是一款靶向趋化因子受体CXCR4的多肽类拮抗剂。在名为COMAT/KEYNOTE-202的2a期临床试验中,能...查看全文
狂拉的麦克斯2019-12-05 22:01
$BioLineRx(BLRX)$ Preliminary data from a Phase 2a clinical trial, COMBAT/KEYNOTE-202, evaluating BioLineRx's (NASDAQ:BLRX) lead oncology candidate BL-8040, combined with Merck's Keytruda and chemo, in metastatic pancreatic cancer patients showed a positive effect (th...查看全文
忘江2018-10-22 13:34
$BioLineRx Ltd. - American Depositary Shares(BLRX)$
The results presented today at a poster discussion session at the European Society for Medical Oncology 2018 Congress, in Munich, Germany, demonstrate that BL-8040 significantly improves T-cell infiltration into the tum...查看全文
静思观语2018-10-21 06:27
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ 在#ESMO18 进一步披露的 关于BL-8040 and Pembrolizumab针对胰腺癌联合用药2a实验结果看起来挺不错的。网页链接查看全文
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001889 Act: 34 Size: 595 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001842 Act: 34 Size: 1 MB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001827 Act: 34 Size: 599 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001769 Act: 34 Size: 588 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001582 Act: 34 Size: 607 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001347 Act: 34 Size: 612 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001285 Act: 34 Size: 595 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001174 Act: 34 Size: 1 MB 网页链接
$BioLineRx(BLRX)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-24-001173 Act: 33 Size: 733 KB 网页链接
$BioLineRx(BLRX)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-24-001095 Act: 34 Size: 14 MB 网页链接